You just read:

PDI, Inc. Subsidiary Interpace Diagnostics Enters Molecular Diagnostics Market with Thyroid and Pancreatic Cancer Test Portfolio Acquisition

News provided by

PDI, Inc.

Aug 13, 2014, 04:03 ET